Baseline characteristics of patients
Characteristic . | Value . |
|---|---|
| Median age, y (range) | 54 (37-67) |
| Immune cytopenias before HCT, no. of patients (%) | 5 (12) |
| Median previous chemotherapy regimens, no. (range) | 3 (1-6) |
| Fludarabine, no. of patients (%) | 36 (88) |
| Corticosteroids, no. of patients (%) | 25 (61) |
| Cyclophosphamide, no. of patients (%) | 25 (61) |
| Chlorambucil, no. of patients (%) | 23 (56) |
| Anthracyclines, no. of patients (%) | 21 (52) |
| Alemtuzumab, no. of patients (%) | 9 (22) |
| Rituximab, no. of patients (%) | 9 (22) |
| Autologous HCT, no. of patients (%) | 11 (27) |
| Status at transplantation, no. of patients (%) | |
| Complete remission | 5 (12) |
| Partial remission | 29 (70) |
| Progressive disease | 7 (17) |
| Median time from diagnosis to HCT, mo (range) | 54 (10-164) |
| Type of donor, no. of patients (%) | |
| Matched related | 24 (58) |
| Matched unrelated | 13 (32) |
| Mismatched unrelated | 4 (10) |
| Median CD34+ cell count, × 106/kg (range) | 5.0 (0.8-16.97) |
| Stem cell source, no. of patients (%) | |
| Peripheral blood stem cells | 35 (85) |
| Bone marrow | 5 (12) |
| Both | 1 (3) |
| CMV serostatus, no. of patients (%) | |
| Donor or recipient positive | 28 (68) |
| Both negative | 13 (32) |
| Median time to follow-up, mo (range) | 15.1 (0.2-62.5) |
Characteristic . | Value . |
|---|---|
| Median age, y (range) | 54 (37-67) |
| Immune cytopenias before HCT, no. of patients (%) | 5 (12) |
| Median previous chemotherapy regimens, no. (range) | 3 (1-6) |
| Fludarabine, no. of patients (%) | 36 (88) |
| Corticosteroids, no. of patients (%) | 25 (61) |
| Cyclophosphamide, no. of patients (%) | 25 (61) |
| Chlorambucil, no. of patients (%) | 23 (56) |
| Anthracyclines, no. of patients (%) | 21 (52) |
| Alemtuzumab, no. of patients (%) | 9 (22) |
| Rituximab, no. of patients (%) | 9 (22) |
| Autologous HCT, no. of patients (%) | 11 (27) |
| Status at transplantation, no. of patients (%) | |
| Complete remission | 5 (12) |
| Partial remission | 29 (70) |
| Progressive disease | 7 (17) |
| Median time from diagnosis to HCT, mo (range) | 54 (10-164) |
| Type of donor, no. of patients (%) | |
| Matched related | 24 (58) |
| Matched unrelated | 13 (32) |
| Mismatched unrelated | 4 (10) |
| Median CD34+ cell count, × 106/kg (range) | 5.0 (0.8-16.97) |
| Stem cell source, no. of patients (%) | |
| Peripheral blood stem cells | 35 (85) |
| Bone marrow | 5 (12) |
| Both | 1 (3) |
| CMV serostatus, no. of patients (%) | |
| Donor or recipient positive | 28 (68) |
| Both negative | 13 (32) |
| Median time to follow-up, mo (range) | 15.1 (0.2-62.5) |